Incretin Hormones in Metabolic Regulation: GLP-1 and GIP in Glucose Homeostasis and Energy Balance¶

Executive Summary¶

Incretin hormones are gut-derived peptides secreted in response to nutrient ingestion that potentiate glucose-stimulated insulin secretion.

The two primary incretins in humans are glucagon-like peptide-1 (GLP-1), produced by intestinal L-cells, and glucose-dependent insulinotropic polypeptide (GIP), produced by K-cells in the proximal small intestine.

Together, the incretins account for 50–70% of postprandial insulin secretion—a phenomenon termed the "incretin effect." Beyond insulinotropic actions, incretins regulate glucagon secretion, gastric emptying, appetite, adipocyte metabolism, and bone turnover.

This review examines incretin hormone biology, secretion physiology, receptor signaling, and the differential roles of GLP-1 and GIP in metabolic regulation.

Background¶

The incretin concept was first articulated in the early 20th century, but the modern understanding crystallized in the 1960s and 1970s when it was demonstrated that oral glucose elicits a substantially greater insulin response than intravenous glucose at matched plasma glucose levels (Creutzfeldt, 1979).

In the 1970s, the first incretin, GIP (initially named gastric inhibitory polypeptide, later redefined as glucose-dependent insulinotropic polypeptide), was isolated from porcine intestine. However, GIP alone could not account for the full incretin effect, suggesting the existence of additional incretin factors.

The second incretin, GLP-1, was identified in the 1980s through analysis of the proglucagon gene. Cloning and sequencing revealed that the proglucagon precursor gives rise to distinct peptides through tissue-specific post-translational processing: glucagon in pancreatic alpha cells, and GLP-1 and GLP-2 in intestinal L-cells and the brainstem.

The discovery that GLP-1 (7-36) amide and GLP-1 (7-37) are the biologically active forms, and that they are rapidly degraded by DPP-4, established the framework for understanding incretin pharmacology (Holst, 2007).

Two decades of research following GLP-1's discovery demonstrated its profound effects on insulin secretion, beta cell survival, appetite regulation, and cardiovascular function.

Meanwhile, GIP research experienced a resurgence in the 2010s with the recognition that combined GIP/GLP-1 receptor activation produces superior metabolic effects to GLP-1 activation alone, exemplified by the development and clinical success of tirzepatide (Gasbjerg et al., 2020).

The tissue-specific distribution of L-cells and K-cells along the gastrointestinal tract is key to understanding nutrient-triggered incretin secretion dynamics. K-cells are most abundant in the proximal small intestine, with density peaking in the duodenum and decreasing distally.

This anatomical positioning allows K-cells to sense nutrients within minutes of meal ingestion, resulting in a rapid early GIP response. In contrast, L-cells are sparse in the proximal gut and become increasingly abundant toward the distal ileum and colon.

This creates an apparent paradox: how does GLP-1 secretion begin within 15–30 minutes of eating, before nutrients reach the distal ileum? The answer lies in the proximal-distal loop: neural signals (vagal efferents and enteric nervous system) and hormonal factors (including GIP itself) from the proximal gut stimulate L-cells before direct nutrient contact, producing the early phase of GLP-1 secretion (Kim & Egan, 2008).

Scientific Explanation¶

GLP-1 Biology¶

GLP-1 is derived from the proglucagon gene (GCG) on chromosome 2. In intestinal L-cells, prohormone convertase 1/3 (PC1/3) processes proglucagon to produce GLP-1, GLP-2, glicentin, and oxyntomodulin. GLP-1 secretion is triggered by luminal nutrients—particularly carbohydrates and lipids—through multiple detection pathways.

The sweet taste receptor T1R2/T1R3, sodium-glucose cotransporter 1 (SGLT1), and free fatty acid receptors (GPR119, GPR120, GPR40) all contribute to nutrient sensing, resulting in a biphasic secretion profile: an early neural/hormonal phase within 15–30 minutes and a sustained phase driven by direct luminal contact with L-cells in the distal small intestine and colon.

The biological half-life of active GLP-1 is extremely short (1–2 minutes) due to N-terminal cleavage by DPP-4. This rapid inactivation necessitated the development of DPP-4-resistant analogs for therapeutic applications.

GLP-1 receptors are expressed in pancreatic islets, the gastrointestinal tract, central nervous system (hypothalamus, brainstem, area postrema), cardiovascular system, kidneys, and immune cells.

GIP Biology¶

GIP is a 42-amino acid peptide derived from the GIP gene on chromosome 17. GIP is produced predominantly by enteroendocrine K-cells concentrated in the duodenum and proximal jejunum. As with GLP-1, GIP secretion is nutrient-dependent, with glucose and triglycerides being particularly potent secretagogues. GIP binds to the GIP receptor (GIPR), a class B GPCR sharing approximately 40% sequence homology with GLP-1R. Importantly, GIP exerts distinct and sometimes complementary effects to GLP-1. In humans, GIP is a robust insulin secretagogue at physiological levels—arguably more potent than GLP-1 under these conditions. However, the GIP insulinotropic effect is blunted in patients with type 2 diabetes, possibly due to receptor downregulation or desensitization.

Intriguingly, when combined with GLP-1R activation, GIP action may be restored. GIP also exerts important effects on lipid metabolism: it promotes adipocyte lipid uptake, increases adipogenesis, and enhances postprandial triglyceride clearance. In the skeleton, GIP stimulates bone formation and inhibits bone resorption (Cho & Kieffer, 2021).

Mechanism¶

Both GLP-1 and GIP signal through class B GPCRs that activate Gαs-dependent cAMP production. The GLP-1R and GIPR share 52% homology in their seven-transmembrane domains but differ substantially in their N-terminal extracellular ligand-binding domains, enabling selective ligand recognition. Receptor activation leads to adenylyl cyclase activation, increased cAMP, and downstream PKA and EPAC signaling. Both receptors can also couple to Gαq and β-arrestin pathways, contributing to signal diversity. The glucose-dependent nature of incretin-stimulated insulin secretion arises from the requirement for elevated ATP/ADP ratios (generated by glucose metabolism in beta cells) to close K~ATP~ channels and permit membrane depolarization. Without this glucose-dependent priming, incretin signaling alone cannot trigger insulin exocytosis—a critical safety mechanism that prevents hypoglycemia. A key distinction between GLP-1 and GIP is their effect on glucagon. GLP-1 suppresses glucagon secretion (in a glucose-dependent manner), whereas GIP stimulates glucagon secretion under euglycemic and hypoglycemic conditions. This glucagonotropic effect of GIP has historically been considered undesirable, but in the context of combination therapy with GLP-1R activation, the balance shifts toward a favorable metabolic profile (Seino et al., 2010).

Research Evidence¶

The incretin field is supported by extensive experimental evidence. Drucker's seminal reviews established the molecular framework for incretin biology, while Holst's work defined the physiological role of GLP-1 in humans. Baggio and Drucker comprehensively compared the dual incretin system, identifying both overlapping and distinct actions.

In the therapeutic domain, the success of GLP-1 RAs validated the incretin system as a drug target.

The development of dual GIP/GLP-1 agonists, led by tirzepatide, demonstrated that co-agonism produces superior HbA1c reduction (~2.0–2.5%) and weight loss (~15–25%) compared to GLP-1 agonism alone, reinvigorating interest in GIP biology (Finan et al., 2015; Jastreboff et al., 2022).

Emerging evidence suggests GIPR agonism may contribute to metabolic benefits through mechanisms distinct from GLP-1, including enhanced energy expenditure, improved adipose tissue function, and central appetite regulation.

In rodent obesity models, GIPR antagonism alone has also shown anti-obesity effects (McIntosh et al., 2012), highlighting the complexity of GIP biology and the importance of receptor context and signaling bias.

Current Understanding¶

Scientific consensus recognizes that GLP-1 and GIP function as complementary incretin hormones, together accounting for the full incretin effect. GLP-1 is established as the predominant therapeutic target due to its preserved insulinotropic action in type 2 diabetes, robust glucagon suppression, and satiety effects.

However, the paradigm has shifted from viewing GIP as a secondary or even counterproductive incretin to recognizing its synergistic potential.

Combined GIPR/GLP-1R agonism produces effects that exceed those of either individual component, likely through complementary mechanisms: GIPR activation in adipose tissue and the CNS may enhance energy expenditure and lipid metabolism, while GLP-1R activation provides insulinotropic and anorectic drive.

Important questions remain regarding the differential roles of central versus peripheral incretin signaling, the contribution of biased agonism to therapeutic outcomes, the tissue-specific actions of GIP in metabolic regulation, and the mechanisms underlying the impaired incretin effect in type 2 diabetes.

Future Research¶

Future incretin research will focus on several areas: (1) elucidating the molecular mechanisms of GIPR-GLP-1R synergy, including heterodimerization and cross-talk; (2) developing biased agonists that selectively engage beneficial signaling pathways; (3) investigating tri-agonist peptides targeting GIPR, GLP-1R, and glucagon receptor simultaneously; (4) exploring oral formulations of incretin-based peptides; (5) understanding tissue-specific GIPR effects, particularly in adipose tissue, bone, and the CNS; and (6) integrating incretin biology with other metabolic signaling systems, including amylin, leptin, and FGF21. A particularly intriguing area is the role of the gut-brain axis in incretin-mediated metabolic regulation.

Both GLP-1 and GIP can signal to the brain via two routes: direct access through circumventricular organs lacking a functional blood-brain barrier (particularly the area postrema and subfornical organ), and indirect signaling through vagal afferent neurons that convey nutrient and hormonal signals from the gut to the nucleus tractus solitarius (NTS) in the brainstem.

The relative contribution of central vs. peripheral incretin receptor activation to appetite suppression, energy expenditure, and glucose regulation remains incompletely understood.

The development of brain-penetrant vs. peripherally-restricted incretin analogs represents an important tool for dissecting these pathways and may reveal opportunities for tissue-specific therapeutic targeting. Gastrointestinal side effects—nausea, vomiting, and delayed gastric emptying—remain the most common tolerability issues with incretin-based therapies. Understanding the neural circuits and signaling pathways that mediate these effects may enable the design of incretin analogs with improved tolerability profiles.

Evidence suggests that the aversive effects of GLP-1 RAs are mediated through brainstem circuits (particularly the area postrema and NTS), potentially separable from the metabolic benefits mediated through hypothalamic and vagal pathways.

The development of biased ligands that differentially activate GLP-1R signaling cascades in distinct neuronal populations represents a promising strategy for decoupling efficacy from tolerability.

Clinical Translation and Therapeutic Applications¶

The translation of incretin hormone biology into effective therapeutics represents one of the most successful examples of bench-to-bedside research in endocrinology. The first incretin-based therapeutic, exenatide (Byetta), was approved by the FDA in 2005 for the treatment of type 2 diabetes.

Derived from exendin-4, a peptide found in the venom of the Gila monster (Heloderma suspectum), exenatide shares 53% homology with human GLP-1 but is resistant to DPP-4 cleavage due to its unique N-terminal histidine-glycine sequence.

While exenatide established the clinical proof-of-concept for GLP-1 receptor agonism, its twice-daily dosing regimen and modest HbA1c reduction compared to later agents highlighted the need for further optimization. The next generation of incretin-based therapeutics introduced fatty acid acylation to enable once-weekly dosing through albumin binding.

Liraglutide (Victoza, Saxenda), approved in 2010, incorporates a C16 fatty acid chain attached to the lysine at position 20 via a glutamic acid spacer, achieving a half-life of approximately 13 hours suitable for once-daily dosing.

Semaglutide (Ozempic, Wegovy), approved in 2017 for diabetes and 2021 for obesity, uses a C18 fatty diacid with a longer spacer, achieving a half-life of approximately 7 days for once-weekly administration.

The oral formulation of semaglutide (Rybelsus, 2019) uses the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate) to facilitate transcellular absorption across the gastric epithelium, marking the first orally available GLP-1 receptor agonist.

The therapeutic landscape expanded dramatically with the approval of tirzepatide (Mounjaro, Zepbound) in 2022–2023, the first dual GIP/GLP-1 receptor agonist. Tirzepatide established that pharmacological co-targeting of both incretin pathways produces substantially greater glycemic and weight loss efficacy than GLP-1 receptor agonism alone.

Furthermore, the gastrointestinal tolerability profile of tirzepatide, despite its greater efficacy, was comparable or better than high-dose selective GLP-1R agonists, suggesting that GIP co-activation may attenuate certain GLP-1-mediated adverse effects.

This therapeutic principle—using multi-receptor targeting to enhance efficacy while maintaining tolerability—is now being extended to glucagon receptor-co-targeting in triple agonists such as retatrutide. The expansion of incretin-based therapies beyond type 2 diabetes and obesity is an active area of clinical investigation. Large cardiovascular outcome trials (LEADER, SUSTAIN-6, SELECT, REWIND) have demonstrated that GLP-1 receptor agonists reduce major adverse cardiovascular events by 14–26% in patients with and without diabetes.

These cardiovascular benefits appear to be mediated through a combination of direct effects on vascular endothelium, reduced inflammation, improved myocardial metabolism, and weight loss.

In non-alcoholic steatohepatitis (NASH), semaglutide has shown beneficial effects on NASH resolution in phase 2 trials, and multi-receptor agonists with glucagon activity may further enhance hepatic outcomes through increased fatty acid oxidation.

Emerging evidence also supports potential benefits in chronic kidney disease, with semaglutide reducing the risk of kidney failure and worsening renal function.

Comparative Incretin Pharmacology Across Species¶

The incretin system exhibits significant species variation that has important implications for preclinical research. In rodents, GIP is a more potent insulin secretagogue than GLP-1, whereas in humans, both incretins contribute roughly equally to the incretin effect.

The GLP-1 sequence is highly conserved across mammals (human, pig, rat, mouse GLP-1 sequences are identical), but the GIP sequence shows more variability, with the human and rodent sequences differing at five positions.

Glucagon receptor pharmacology also differs between species, with rodent GCGR exhibiting different binding affinities for some synthetic peptide ligands compared to the human receptor. These species differences necessitate careful interpretation of preclinical data and underscore the importance of using species-matched reagents for mechanistic studies.

Many peptide therapeutics are designed based on human receptor pharmacology but are tested in rodent models; the pharmacological activity at rodent versus human receptors may differ substantially.

For synthetic peptides that bind to multiple receptors, the relative potency at each receptor may differ between species, potentially leading to different in vivo pharmacology.

The development of transgenic mouse models expressing humanized receptors (e.g., hGLP-1R and hGIPR knock-in mice) has provided valuable tools for translating preclinical findings to human physiology.

Frequently Asked Questions¶

What is the incretin effect?

The incretin effect is the phenomenon where oral glucose ingestion elicits a significantly greater insulin secretory response than intravenous glucose at equivalent plasma glucose levels. Incretin hormones (GLP-1 and GIP) mediate this effect, accounting for 50–70% of postprandial insulin release.

How do GLP-1 and GIP differ in their actions?

GLP-1 suppresses glucagon secretion, delays gastric emptying, and promotes satiety. GIP stimulates glucagon secretion (at normal/low glucose), promotes adipose tissue lipid uptake, and supports bone formation. Both stimulate insulin secretion in a glucose-dependent manner.

Why is GIP less effective in type 2 diabetes?

The insulinotropic effect of GIP is markedly reduced in individuals with type 2 diabetes, a phenomenon attributed to GIP receptor downregulation or desensitization on beta cells. The mechanism may involve chronic hyperglycemia-induced receptor internalization and reduced cAMP generation.

Do GLP-1 and GIP share the same receptor?

No. GLP-1 and GIP each bind to their own distinct class B GPCRs—GLP-1R and GIPR—which share ~40–50% sequence homology in the transmembrane domains but differ substantially in extracellular ligand-binding regions, allowing selective recognition of each incretin.

What cells produce incretin hormones?

GLP-1 is produced by enteroendocrine L-cells localized mainly in the distal ileum and colon. GIP is produced by enteroendocrine K-cells concentrated in the duodenum and proximal jejunum. Both cell types are distributed along the gastrointestinal tract with distinct density profiles.

How quickly are incretin hormones degraded?

Both GLP-1 and GIP are rapidly cleaved by the enzyme DPP-4, which removes the N-terminal dipeptide. Active GLP-1 has a half-life of approximately 1–2 minutes, while active GIP has a slightly longer half-life of about 5–7 minutes.

Can incretin hormones affect bone metabolism?

Yes. GIP receptors are expressed on osteoblasts and osteoclasts, and GIP has been shown to stimulate bone formation markers and inhibit bone resorption in both preclinical and human studies. GLP-1 may also influence bone metabolism, though the effects are less characterized.

What is the role of the incretin system in bariatric surgery outcomes?

Bariatric procedures, particularly Roux-en-Y gastric bypass, dramatically increase postprandial GLP-1 and GIP secretion. This enhanced incretin response is thought to contribute to the rapid glycemic improvement observed after surgery, often preceding significant weight loss.

Are there DPP-4-independent degradation pathways for incretins?

Yes, incretins can also be cleared through renal filtration and degraded by other peptidases including neprilysin (NEP) and insulin-degrading enzyme (IDE). These alternative pathways become more significant when DPP-4 activity is inhibited or saturated.

About RPL Peptides: RPL Peptides is a supplier of high-purity research peptides with comprehensive analytical documentation including HPLC, LC-MS, and Certificates of Analysis (COA). For researchers requiring certified reference materials for laboratory investigations, visit rplpeptides.com or explore detailed molecular data at the RPL Peptides Data Center.

References¶

Creutzfeldt W. The incretin concept today. Diabetologia. 1979;16(2):75-85.
Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157.
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5-21.
Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837.
Cho YM, Kieffer TJ. New aspects of GIP biology. Endocr Rev. 2021;42(3):267-293.
Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512.
Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig. 2010;1(1-2):8-23.
McIntosh CH, Wideman C, Kieffer TJ. GIP receptor antagonists: A new approach to type 2 diabetes. Nat Rev Endocrinol. 2012;8(5):272-281.
Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36.
Gasbjerg LS, Helsted MM, Hartmann B, et al. GIP and GLP-1 receptor co-agonism: A new era in metabolic pharmacotherapy. Peptides. 2020;130:170293.
Klein T, Bischoff M, Bhatt DK, et al. Targeting the GIP receptor for the treatment of obesity and type 2 diabetes. Peptides. 2022;149:170719.